Compare Koken Ltd. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 6.43% signifying low profitability per unit of shareholders funds
2
High Debt company with Weak Long Term Fundamental Strength
3
Negative results in Jun 26
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 9,351 Million (Micro Cap)
11.00
NA
0.08%
0.17
5.63%
0.68
Revenue and Profits:
Net Sales:
2,472 Million
(Quarterly Results - Jun 2026)
Net Profit:
104 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.87%
0%
-7.87%
6 Months
-2.96%
0%
-2.96%
1 Year
7.01%
0%
7.01%
2 Years
16.71%
0%
16.71%
3 Years
9.01%
0%
9.01%
4 Years
6.19%
0%
6.19%
5 Years
-4.66%
0%
-4.66%
Koken Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.91%
EBIT Growth (5y)
-2.97%
EBIT to Interest (avg)
21.10
Debt to EBITDA (avg)
1.75
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.58
Tax Ratio
30.13%
Dividend Payout Ratio
27.80%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.74%
ROE (avg)
6.43%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.64
EV to EBIT
9.56
EV to EBITDA
6.98
EV to Capital Employed
0.69
EV to Sales
0.93
PEG Ratio
NA
Dividend Yield
0.09%
ROCE (Latest)
7.22%
ROE (Latest)
5.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
2,472.00
2,819.80
-12.33%
Operating Profit (PBDIT) excl Other Income
274.80
355.30
-22.66%
Interest
20.50
18.10
13.26%
Exceptional Items
10.20
0.00
Consolidate Net Profit
104.00
143.30
-27.42%
Operating Profit Margin (Excl OI)
64.20%
88.30%
-2.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -12.33% vs -36.10% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -27.42% vs -72.48% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
11,857.10
10,762.40
10.17%
Operating Profit (PBDIT) excl Other Income
1,688.10
1,451.00
16.34%
Interest
59.70
47.50
25.68%
Exceptional Items
0.00
31.60
-100.00%
Consolidate Net Profit
885.30
722.10
22.60%
Operating Profit Margin (Excl OI)
107.20%
93.80%
1.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.17% vs 1.66% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 22.60% vs 3.00% in Dec 2024
About Koken Ltd. 
Koken Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






